Newsfeeds Archive - Page 18948 of 19074

1 minute read

NewAge, Inc. Announces Departure Of CFO Kevin Manion; Lawrence Perkins To Assume role Of Principal Financial Officer On An Interim Basis

July 8, 6:01 AM

NewAge, Inc. (NASDAQ:NBEV) (the "Company" or "NewAge"), today announced that Kevin Manion, Chief Financial Officer, departed the Company as of July 1, 2022. Lawrence Perkins, who along with his

NBEV

1 minute read

Hyatt Hotels Debuts Park Hyatt Brand In Indonesia

By Shivani Kumaresan

July 8, 5:58 AM

Hyatt Hotels Corp (NYSE:H) has opened Park Hyatt Jakarta, marking the entry of the hospitality brand in Indonesia. The hotel…

1 minute read

American Rebel Holdings Priced Private Placement of 11,711,712 Shares Plus Warrants to Purchase 23,423,424 Shares @$1.11/Share/Warrants

By Charles Gross

July 8, 5:46 AM

American Rebel Holdings, Inc.

AREB

3 minute read

Why U.S. Stock Futures Are Down Ahead Of Key Jobs Report For June

By Lisa Levin

July 8, 5:25 AM

Pre-open movers U.S. stock futures traded lower in early pre-market trade on Thursday ahead of the much-awaited jobs report for June.

GME

1 minute read

Needham Maintains Buy on Intercept Pharmaceuticals, Lowers Price Target to $22

By Benzinga Newsdesk

July 8, 5:14 AM

Needham analyst Joseph Stringer maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy and lowers the price target from $25 to $22.

ICPT

1 minute read

Keybanc Maintains Overweight on Materion, Lowers Price Target to $100

By Benzinga Newsdesk

July 8, 5:05 AM

Keybanc analyst Philip Gibbs maintains Materion (NYSE:MTRN) with a Overweight and lowers the price target from $106 to $100.

MTRN

1 minute read

Keybanc Maintains Overweight on Aspen Technology, Raises Price Target to $210

By Benzinga Newsdesk

July 8, 5:03 AM

Keybanc analyst Jason Celino maintains Aspen Technology (NASDAQ:AZPN) with a Overweight and raises the price target from $175 to $210.

AZPN

1 minute read

Benchmark Initiates Coverage On NOW with Buy Rating, Announces Price Target of $13

By Benzinga Newsdesk

July 8, 5:01 AM

Benchmark analyst Douglas Becker initiates coverage on NOW (NYSE:DNOW) with a Buy rating and announces Price Target of $13.

DNOW

1 minute read

Oppenheimer Initiates Coverage On Blueprint Medicines with Outperform Rating, Announces Price Target of $80

By Benzinga Newsdesk

July 8, 4:59 AM

Oppenheimer analyst Matthew Biegler initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Outperform rating and announces Price Target of $80.

BPMC